These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 4006382)

  • 1. A molecular theory of recognition and activation at a 5-HT receptor based on a quantum chemical approach to structure activity relationships.
    Osman R; Weinstein H; Topiol S; Rubenstein L
    Clin Physiol Biochem; 1985; 3(2-3):80-8. PubMed ID: 4006382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A molecular model for activation of a 5-hydroxytryptamine receptor.
    Osman R; Topiol S; Rubenstein L; Weinstein H
    Mol Pharmacol; 1987 Nov; 32(5):699-705. PubMed ID: 2824984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
    Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
    J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions.
    Pauwels PJ; Gouble A; Wurch T
    Biochem J; 1999 Oct; 343 Pt 2(Pt 2):435-42. PubMed ID: 10510311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors.
    Blaazer AR; Smid P; Kruse CG
    ChemMedChem; 2008 Sep; 3(9):1299-309. PubMed ID: 18666267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors.
    Görnemann T; Hübner H; Gmeiner P; Horowski R; Latté KP; Flieger M; Pertz HH
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1136-45. PubMed ID: 18096760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
    Medina RA; Sallander J; Benhamú B; Porras E; Campillo M; Pardo L; López-Rodríguez ML
    J Med Chem; 2009 Apr; 52(8):2384-92. PubMed ID: 19326916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.
    López-Rodríguez ML; Porras E; Morcillo MJ; Benhamú B; Soto LJ; Lavandera JL; Ramos JA; Olivella M; Campillo M; Pardo L
    J Med Chem; 2003 Dec; 46(26):5638-50. PubMed ID: 14667218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular actions of propofol on human 5-HT3A receptors: enhancement as well as inhibition by closely related phenol derivatives.
    Barann M; Linden I; Witten S; Urban BW
    Anesth Analg; 2008 Mar; 106(3):846-57, table of contents. PubMed ID: 18292429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
    Chambers JJ; Parrish JC; Jensen NH; Kurrasch-Orbaugh DM; Marona-Lewicka D; Nichols DE
    J Med Chem; 2003 Jul; 46(16):3526-35. PubMed ID: 12877591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism.
    Kristiansen K; Kroeze WK; Willins DL; Gelber EI; Savage JE; Glennon RA; Roth BL
    J Pharmacol Exp Ther; 2000 Jun; 293(3):735-46. PubMed ID: 10869371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Creation, expression, and characterization of a constitutively active mutant of the human serotonin 5-HT6 receptor.
    Purohit A; Herrick-Davis K; Teitler M
    Synapse; 2003 Mar; 47(3):218-24. PubMed ID: 12494404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 3-aminochromans as potential pharmacological tools for the serotonin 5-HT(7) receptor.
    Holmberg P; Tedenborg L; Rosqvist S; Johansson AM
    Bioorg Med Chem Lett; 2005 Feb; 15(3):747-50. PubMed ID: 15664850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine.
    Grottick AJ; Corrigall WA; Higgins GA
    Psychopharmacology (Berl); 2001 Sep; 157(3):292-8. PubMed ID: 11605085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
    Egan C; Grinde E; Dupre A; Roth BL; Hake M; Teitler M; Herrick-Davis K
    Synapse; 2000 Feb; 35(2):144-50. PubMed ID: 10611640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.
    Holenz J; Pauwels PJ; Díaz JL; Mercè R; Codony X; Buschmann H
    Drug Discov Today; 2006 Apr; 11(7-8):283-99. PubMed ID: 16580970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
    Glusa E; Markwardt F
    Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
    Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
    J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.